Medical Therapy. Pharmacokinetics and Pharmacology

Lower paediatric exposure in pulmonary arterial hypertension: Translating population pharmacokinetics into dose individualization

Zhichao Zhao, Ting ShenAffiliated Yangming Hospital of Ningbo University.China British Journal of Clinical PharmacologyBr J Clin Pharmacol 2026; DOI: 10.1002/bcp.70769 AbstractAbstract Not Available CategoryMedical Therapy. Pharmacokinetics and Pharmacology Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication Article Access Free PDF File or Full Text Article Available […]

Lower paediatric exposure in pulmonary arterial hypertension: Translating population pharmacokinetics into dose individualization Read More »

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs

Motoyasu Miura, Shimako Tanaka, Ririka Aihara, Shun Yamamoto, Yasumi Nakashima, Yasuharu Kashiwagura, Akio Hakamata, Sachiko Miyakawa, Mariko Tatsuguchi, Keiichi Odagiri, Noriyuki Namiki, Naoki Inui, Hiroshi Watanabe, Shinya UchidaUniversity of Shizuoka. Seirei Hamamatsu General Hospital. Hamamatsu University School of Medicine.Japan British Journal of Clinical PharmacologyBr J Clin Pharmacol 2026; DOI: 10.1002/bcp.70676 AbstractAims: Pulmonary arterial hypertension (PAH) is a

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs Read More »

L-Citrulline: Novel Pharmacotherapy to Improve Outcomes in Infants and Children at Risk of Systemic or Pulmonary Vascular Disease

Candice D. Fike, Frederick E. Barr, Judy L. AschnerUniversity of Utah Health. Diversified Search Group. Hackensack Meridian School of Medicine.United States PharmaceuticalsPharmaceuticals 2026; 19: DOI: 10.3390/ph19060896 AbstractInfants and children suffering from a variety of heart, lung, and blood disorders are known to be at risk of developing systemic or pulmonary vascular disease. Despite progress made in

L-Citrulline: Novel Pharmacotherapy to Improve Outcomes in Infants and Children at Risk of Systemic or Pulmonary Vascular Disease Read More »

L-Citrulline in Maternal-Fetal and Neonatal Health: Metabolic Mechanisms and Emerging Therapeutic Applications

Ana Collins-Smith, Sangeeta Jain, Sunil JainUniversity of Texas Medical Branch at Galveston.United States NutrientsNutrients 2026; 18: DOI: 10.3390/nu18121923 AbstractL-citrulline is a non-protein amino acid with critical roles in perinatal and neonatal physiology through the intestinal-renal arginine-citrulline axis and nitric oxide (NO) production. During pregnancy, L-citrulline supports placental angiogenesis, vascular adaptation, and fetal growth through augmentation of

L-Citrulline in Maternal-Fetal and Neonatal Health: Metabolic Mechanisms and Emerging Therapeutic Applications Read More »

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial

Rolf M. F. Berger, D. Dunbar Ivy, Julian I. Borissoff, Sofija Cerovic, Dénes Csonka, Tatiana Remenová, Dominik Richard, Matthieu Villeneuve, Maurice BeghettiBeatrix Children’s Hospital, University Medical Center Groningen and University of Groningen. Children’s Hospital Colorado. Johnson & Johnson. University Hospitals of Geneva.Netherlands, United States and Switzerland Journal of PediatricsJ Pediatr 2026; DOI: 10.1016/j.jpeds.2026.115057 AbstractObjectives: To evaluate pharmacokinetics

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial Read More »

Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites

Mohammad Ahmad Bik, Duygu Eryavuz, Onmaz, Karem Mazin Kamil Gharab, Fadime Karaman, Sedat Abusoglu, Abdullah Sivrikaya, Ali UnluSelcuk University. Mustansiriyah University.Turkey and Iraq Indian Journal of Clinical BiochemistryIndian J Clin Biochem 2026; 41: 113-119DOI: 10.1007/s12291-024-01215-x AbstractPulmonary arterial hypertension (PAH) is a lethal, progressive disease with a complex pathogenesis. Bosentan, a dual endothelin receptor antagonist, and sildenafil,

Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites Read More »

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study

Yao Zhu, Jiongzhi He, Miner Cai, Lijun Wen, Minxu LiDongguan Maternal and Child Health Care Hospital. First Affiliated Hospital of Jinan University.China Translational PediatricsTransl Pediatr 2025; 14: 3305-3317DOI: 10.21037/tp-2025-535 AbstractBackground: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening emergency in neonatal intensive care. Traditional treatments such as cylinder-based nitric oxide (NO) delivery systems rely on

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study Read More »

A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertension

Maurice Beghetti, Lene Nygaard Axelsen, Julian I. Borissoff, Mahdi Farhan, Simon Grill, Sining Leng, Alberto Russu, Catherine Lesage, Tatiana Remeňová, Shu-Fang Hsu Schmitz, Shahin MoledinaUniversity Hospitals of Geneva. Johnson & Johnson. Great Ormond Street Hospital. Switzerland and United Kingdom ChestChest 2025; DOI: 10.1016/j.chest.2025.12.013 AbstractBackground: Selexipag is an oral selective prostacyclin receptor agonist approved for treating pulmonary arterial

A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertension Read More »

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension

Yanmin Pei, Meidong Si, Xuemei Ma, Siyun Liu, Fang Zhao, Ru ZhouNingxia Medical University and General Hospital of Ningxia Medical University.China Drug Design, Development and TherapyDrug Des Dev Ther 2025; 19: 11119-11144DOI: 10.2147/DDDT.S547530 AbstractPurpose: 18β-Glycyrrhetinic acid liposomes (18β-GA-Lips) were developed to enhance lung-specific drug delivery and optimize the therapeutic management of pulmonary arterial hypertension (PAH).Methods: 18β-GA-Lips of varying

Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension Read More »

Systemic Sirolimus Monitoring in Pediatric Pulmonary Vein Stenosis

Heather Meluskey, Bridget Blowey, Anna B. O’Brien, Michael L. O’Byrne, Jonathan J. Rome, David B. Frank, Catherine M. Avitabile, Mudit Gupta, Jessica Tang, Kimberly L. Butler, Constantine D. Mavroudis, Stephanie Fuller, Ryan CallahanChildren’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania. Dell School of Medicine at the University of Texas.

Systemic Sirolimus Monitoring in Pediatric Pulmonary Vein Stenosis Read More »

Scroll to Top